Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03997812 · ClinicalTrials.gov registry record · Phase 2

Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Postoperative Pain Following Bunionectomy

A Phase 2 study of Pain, Postoperative, sponsored by Vivozon.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target
2
Study locations

NCT03997812 is a Phase 2 study of Pain, Postoperative that has completed, run by Vivozon. The registered enrollment target is 60 participants, below the 272-participant average among 108 other Pain, Postoperative trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03997812, a Phase 2 study of Pain, Postoperative, has completed, sponsored by Vivozon.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this phase 2 study is to evaluate the efficacy and safety of an analgesic drug candidate, VVZ-149 Injections for treating post-operative pain following bunionectomy.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG VVZ-149 Injections

Study Locations (2)

California

  • Anaheim Clinical Trials - Anaheim

Utah

  • JBR Clinical Research - Salt Lake City

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2019-05-23
Est. Completion 2019-08-21
Phase Phase 2

Sponsor

Vivozon

5 total trials

What the Registry Record Tells You About NCT03997812

The ClinicalTrials.gov registry entry for NCT03997812 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 272-participant average among 108 other Pain, Postoperative trials with a reported enrollment target (78% lower). The listed sponsor is Vivozon, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain, Postoperative appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03997812 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Utah.

Frequently Asked Questions

What is clinical trial NCT03997812 about?

NCT03997812 is a clinical study titled "Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Postoperative Pain Following Bunionectomy". The purpose of this phase 2 study is to evaluate the efficacy and safety of an analgesic drug candidate, VVZ-149 Injections for treating post-operative pain following bunionectomy.

What is the current status of trial NCT03997812?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2019-05-23. Estimated completion is 2019-08-21.

What conditions does trial NCT03997812 study?

This clinical trial studies the following conditions: Pain, Postoperative.

What interventions are being tested in trial NCT03997812?

The interventions under investigation include: Placebo (DRUG), VVZ-149 Injections (DRUG).

Who is sponsoring clinical trial NCT03997812?

This trial is sponsored by Vivozon, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03997812 being conducted?

This trial has 2 study locations across California, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain, Postoperative

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.